Bailitanheng (688506.SH): The first subject was enrolled in the phase III clinical trial of BL-B01D1 for locally advanced or metastatic triple-negative breast cancer.

On July 3rd, Gelunhui reported that Bailitianheng (688506.SH) announced that the Phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) injection, an innovative biological drug independently developed and used alone for unresectable locally advanced or metastatic triple-negative breast cancer that has failed previously treated with taxanes, has completed the first subject enrollment. So far, BL-B01D1 monotherapy has been registered for Phase III clinical trials in domestic terminal nasopharyngeal carcinoma, line 2 esophageal squamous cell carcinoma, HR+HER2- breast cancer, EGFR mutation type non-small cell lung cancer, and EGFR wild-type non-small cell lung cancer.

Gelonghui FinanceJul 3 07:36 ET

Express News | Biokin Pharma Says It Plans to Issue Shares and List in Hong Kong

ReutersJun 21 08:21 ET

Baili Tianheng (688506.SH): The injection of BL-M17D1 (ADC) project for the treatment of advanced solid tumors has been approved for Phase I clinical trials.

On June 21st, Gelonhui reported that Bailitianheng (688506.SH) announced to have received the official approval notice of"Drug Clinical Trial Approval" issued by the National Medical Products Administration (NMPA). The company's independent research and development of innovative biomedicine BL-M17D1 (ADC) clinical trial received approval. BL-M17D1 is an ADC drug derived from the same new small molecule technology platform as BL-B16D1, and shares the same new "linker + toxin" platform as BL-B16D1. It is indicated for advanced solid tumors.

Gelonghui FinanceJun 21 07:45 ET

Bailey Tianheng (688506.SH): plans to issue H shares and list on the Hong Kong Stock Exchange.

On June 21st, Gelonhui reported that in order to further support the development of the company's international business and better utilize domestic and overseas financing platforms, consolidate the company's fast-growing capital reserve, and support the global development of the company's many innovative products in Europe, America, Japan, and other international markets, it will vigorously promote the implementation of the strategy of making the company a multinational pharmaceutical enterprise (MNC) with globally leading advantages in the field of cancer drug use. The company plans to issue shares (H shares) overseas and list on the main board of the Hong Kong Stock Exchange (referred to as the "Hong Kong Stock Exchange") to select within the valid period of the shareholders' meeting resolution.

Gelonghui FinanceJun 21 07:42 ET

Bailey Tianheng (688506.SH): BL-B01D1 (EGFR×HER3-ADC) for locally advanced or metastatic EGFR wild-type non-small cell lung cancer phase III clinical trial completed the first patient enrollment

On June 2, Ge Longhui (688506.SH) announced that the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy independently developed by the company for injectable BL-B01D1 (EGFR×HER3-ADC) monotherapy for locally advanced or metastatic EGFR wild non-small cell lung cancer that has previously been treated with anti-PD-1/PD-L1 monoclonal antibodies and failed platinum-containing chemotherapy treatment has recently completed the first case of participants.

Gelonghui FinanceJun 2 03:44 ET

Baili Tianheng (688506.SH): BL-B01D1 completed the first patient enrollment in the phase III clinical trial of locally advanced or metastatic non-small cell lung cancer for EGFR-sensitive mutations that failed EGFR-TKI treatment

Gelonghui, May 29丨Bailey Tianheng (688506.SH) announced that BL-B01D1 is a globally exclusive dual-antibody ADC drug independently developed by the company that can target EGFR and HER3 at the same time in clinical trials. Recently, the clinical study of BL-B01D1 monotherapy for non-small cell lung cancer has entered the phase III clinical trial stage and completed the enrollment of the first test subjects. Up to now, the domestic Phase III registered clinical trial of BL-B01D1 as a single agent to treat terminal nasopharyngeal cancer, second-line esophageal squamous cell carcinoma, and HR+HER2-breast cancer is in the phase III registration phase of subjects.

Gelonghui FinanceMay 29 07:34 ET